Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This very specific treatment for hemophilia will have other ramifications influencing the whole spectrum of the drug discovery field and future examinations of feasible (concievable) medical cost:
https://www.bloomberg.com/news/articles/2022-11-23/world-s-most-expensive-drug-csl-hemgenix-hemophilia-approved-by-fda
MICT: you are correct plus 3 as had MICT 2.70 last year and put out the beggars cup at .41 cent this years low, ............TMNA new on the "heal of the hunt" but took some lash on missing the MICT 3 bagger this year as watched TMNA "gem" down..
Yes thought the study I linked was notable because although I am not an MD or in that setting, I always believed that Lyme disease was most "ample" infliction I knew of, that was always clouded with mystery. That is to say it is bad enough being told one has Lyme disease, but yet at same time never certain it was really Lyme disease.
As a precaution I have been content to stay in sparsely wooded urban settings.
MICS kinship: I saw that glory , and drunk heavily from that cup!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169465548
MICS kinship: I saw that glory , and dru8nk heaviloy:
This study is the first to use transcriptomics as a blood test to measure RNA levels in patients with long-term Lyme disease, and a study in search of a Co. I could actually invest in. Notable is suspected predatory practices by benefactor of this research center has probably made this research possible.
https://medicalxpress.com/news/2022-11-genes-potentially-long-term-lyme-disease.html?utm_source=nwletter&utm_medium=email&utm_campaign=daily-nwletter
One targeted therapy oncolytic virotherapy uses a virus that infects and breaks down only cancer cells
New money is still coming in as 114 current studies, and today:
https://endpts.com/can-an-oncolytic-virus-therapy-challenge-the-longstanding-standard-of-care-in-bladder-cancer-cg-oncology-has-120m-to-find-out/
And yet I personally conclude this therapy although on the cusp of major breakthroughs is not without major investment perils., but a good catch all 'meme" (OV's) to garner much needed additional research money.
In the building of an opinion considering the future success of OV's, this summation (about a year old) of the spectrum of recent developments comprising the current challenges of OV's, still required from additional contributions from the areas of molecular biology, structural biology, immunology, genomics, and bioinformatics, merits very complex attentions.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474975/#:~:text=The%20clinical%20use%20of%20oncolytic,in%20the%20patient's%20clinical%20condition.
Real reason I bought TMNA, was convinced I would oversee a stock perturbation:
"a deviation of a system, moving object, or process from its regular or normal state or path, caused by an outside influence."
TMNA had run of .76 to 1.24 after heady finacials, but in practical terms vol. was starved just like my startle. as the timing for some reaction matches a parallel trading trend with higher volume hidden from our eyes.
TMNA 1.24 went through again.
Difficult to assess are the value to other players (drug Co's.) of any unique strategy improvements. And also in my opinion,
all such ilk offer sure fire shorting glories after an almost accumulated thoughtless posse algorithm selection, as boilerplate cautions such as this always prevail: "Assessment of the clinical benefit of cancer treatments can be highly subjective, influenced by both perspective and context. Such assessments are required in regulatory and policy decision-making, but consistency between jurisdictions is often lacking. Clear and consistent standards for determining when a treatment offers a meaningful benefit, relative to the current standard of care, can help to address issues of equity and transparency in health technology assessment."
Difficult to assess are the value to other players of any unique strategy improvement.
Cart-T merging with Crisper seems promising but study does not address the faithful impending immunoediting useful for cancer cells to avoid eradication after such a complicated expensive strategic tactic.
https://www.nature.com/articles/d41586-022-03676-7?utm_source=Nature+Briefing&utm_campaign=0f8d4b9fcf-briefing-dy-20221111&utm_medium=email&utm_term=0_c9dfd39373-0f8d4b9fcf-44970129
https://en.wikipedia.org/wiki/Immunoediting
With such low vol. I have been at the shoot out trying to catch a stray bullet let go
almost arbitrarily while my vest still works..
Wonder if more oncologists will wear a button in their clinical setting with some logo spelling Imfinzi, as its promise for more cancers expands ?
"Imfinzi is also the only approved immunotherapy in unresectable or metastatic biliary tract cancer and hepatocellular carcinoma (in combination with Imjudo).................",
TMNA: I could be wrong but bought this because I have stock insecurity.
Found some coins under the cushion today, had to go deep as almost fell under the innerspring.
SONN dipped but has new true believers.
TMNA 1.29 HOD sopped up some of those weeping puddles!
Nice average 15+ bagger for short 22 month wait!
Your first post there on TGLO?
TGLO .45.
Virtual trials........love the conclusions of this money saving time saving strategy, but the understanding of it for me is at a standstill.
https://medicalxpress.com/news/2022-11-scientists-alzheimer-drugs-head-to-head-first-ever.html?utm_source=nwletter&utm_medium=email&utm_campaign=daily-nwletter
TMNA scraping off some fumes to vent later.
TMNA minutes ago it was like this there were 50K of them @1.07 and 500 of me @1.04, well I folded like a cheap suit and got the 1.07.
I have been smacked in the head before trying to brag how I stole cheap shares.
Lot of juxtapositions, i tried to elbow my way in forcibly.
SONN 2.45
OT: guy named STEPHEN SCHERTZER claims this guy has best all time record
return performance trading stocks.:
https://en.wikipedia.org/wiki/Jim_Simons_(mathematician)
Saw the stack and realized it produced no vol., then realized either direction is fortuitous, then looked up the word fortuitous to kill time, and realized the stacking was presented to just look fortuitous.
The absolute knowledge that no drug can be proven to ever fail under any future circumstance aways imbeds a (marketable) positive bias after dismal drug trial failures.
Exhibit A:
RE: Pembrolizumab, sold under the brand name Keytruda, now first line treatment of numerous metastatic cancers,( having generated over 17 billion in revenues to date ). In early 2010, Merck terminated development and began preparing to out-license it...................in short it was only the knowledge of limiting its use with patients matching biomarker criteria which made Merck start from almost scratch to get into this field in major depth, as this drug only came as an incidental package in buyout from Schering-Plough, and in 2013 for its first time, Merck applied for and won a breakthrough therapy designation for it.
https://en.wikipedia.org/wiki/Pembrolizumab
I am waiting for a single cancer house to publish something like this:
We fired our PR staff waxing versions of possible success, as we are now the first to announce that regarding our leading drug, our initiatives beyond any scientific doubt support announcing a complete enduring 100% cure rate with no side effects . We also wish to announce ala Marlon Brando earlier, we will not accept any awards or
participate in promoting any non-scientific praise.
EPIX : its another example of the new found commitment and election of the necessary focus on these "possible" signaling pathways or processes managing "bad traffic"
to reverse the course of diseases like cancer. I personally like the notion of following the course of a disease closer to the initial handoff of errant influences promoting a disease, than hearing that some drug influence happens to cause a favorable outcome by crude trial and error.as an example: "starting in the late 19th century there had been reports of the antibacterial properties of Penicillium mold, but scientists were unable to discern what process was causing the effect".
EPIX: New method for blocking androgen receptor signaling which may be main driver of prostate cancer progression showed progress in preclinical setting, and gave stock a double yesterday.
https://www.streetinsider.com/Corporate+News/ESSA+Pharma+%28EPIX%29+Presents+Preclinical+Data+for+its+First+Generation+Androgen+Receptor+N-Terminal+Domain+Degrader/20750059.html
In my opinion, both complementary and necessary, the misinterpretation of landmark scientific breakthroughs equal immediate engagement and funding, and also equal, exaggerated hopes in a new pill.
Decades of research has speed up these consequences, and this article may provide a tidy example ( replicated in hundreds of other research timetables), of a single aspect of this landscape, zooming in on the real pace ( of human disease benefits) attempting to overcome unknown complexities relating to a single mutation.
"Cancer drugs are closing in on some of the deadliest mutations"
https://www.nature.com/articles/d41586-022-03392-utm_source=Nature+Briefing&utm_campaign=0d6c160cd2-briefing-dy-20221025&utm_medium=email&utm_term=0_c9dfd39373-0d6c160cd2-44970129
Personally I have no objections to these forces of slow progress, only the cautionary aspects valuable to investors.
TCDA down to .56 cents from 11.84 high on Friday, and still may be too high?
I am told that yen and euro are way below historic prices for decades, I once out of pure luck invested in an Australian bond which paid over 4% and sold just before its collapse at a 30% return when converted back into USA dollars (about 9 years ago).
Soros did his billions on the British pound bet decades before...wonder if something similar is brewing in about 6 months?
Oh oh signs of first 100 billion dollar "something".
These blokes and ilk have already given 100 million each to explore such avenues.
https://www.technologyreview.com/2021/09/04/1034364/altos-labs-silicon-valleys-jeff-bezos-milner-bet-living-forever/
https://medicalxpress.com/news/2022-10-extracellular-vesicles-young-mice-older.html?utm_source=nwletter&utm_medium=email&utm_campaign=daily-nwletter
IMHO all diseases can be eventually controlled, the will to make all the sacrifices necessary to speed up all resources to shorten the time that becomes a fact, can never be "cured".
Colonoscopies ( the polyp nipping dilemma):
"This result points to the value of continued screening," Dahut says. The ACS also says it's important to consider that participants in the study were screened sometime between 2009 to 2014, so some got their colonoscopy as recently as 8 years ago. "The time from polyps to cancer to mortality is almost always greater than this — so a much longer follow-up is needed," an ACS statement concludes. Over time, the reduction in cancer or deaths could be greater.
https://www.npr.org/sections/health-shots/2022/10/13/1128531054/colonoscopies-save-lives-doctors-push-back-against-european-study-that-casts-dou